Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Fybogel Hi-Fibre Orange 3.5g effervescent granules sachets
0106010E0BKAAAD
|
Senokot (Ispahulag husk) | Ispaghula husk | Gastro-Intestinal System | 10,261 |
|
Omeprazole 20mg/5ml oral suspension sugar free
0103050P0AABVBV
|
Omeprazole | Omeprazole | Gastro-Intestinal System | 10,237 |
|
Gaviscon Double Action chewable tablets mint
0101021B0BEARA0
|
Gaviscon | Alginic acid compound preparations | Gastro-Intestinal System | 10,201 |
|
Omeprazole 40mg gastro-resistant tablets
0103050P0AABEBE
|
Omeprazole | Omeprazole | Gastro-Intestinal System | 9,547 |
|
Cinchocaine 1mg / Prednisolone hexanoate 1.3mg suppositories
0107020P0AAADAD
|
Cinchocaine/prednisolone hexonate | Prednisolone | Gastro-Intestinal System | 9,519 |
|
Macrogol compound half-strength oral pdr sach NPF sugar free
0106040M0AAABAB
|
Macrogol 3350 | Macrogol 3350 | Gastro-Intestinal System | 9,490 |
|
Ursodeoxycholic acid 150mg tablets
0109010U0AAAAAA
|
Ursodeoxycholic acid | Ursodeoxycholic acid | Gastro-Intestinal System | 9,444 |
|
Omeprazole 40mg dispersible gastro-resistant tablets
0103050P0AAAPAP
|
Omeprazole | Omeprazole | Gastro-Intestinal System | 9,203 |
|
Pentasa 1g modified-release granules sachets
0105010B0BCAEAN
|
Pentasa | Mesalazine (Systemic) | Gastro-Intestinal System | 9,037 |
|
Glycerol 2g suppositories
0106020L0AAABAB
|
Glycerol (Systemic) | Glycerol | Gastro-Intestinal System | 8,648 |
|
Colofac MR 200mg capsules
0102000P0BCAEAD
|
Colofac | Mebeverine hydrochloride | Gastro-Intestinal System | 8,608 |
|
Gaviscon Double Action Liquid peppermint
0101021B0BEASA0
|
Gaviscon | Alginic acid compound preparations | Gastro-Intestinal System | 8,403 |
|
Fybogel Mebeverine effervescent granules sachets orange
0102000X0BCAAAA
|
Fybogel mebeverine | Mebeverine hydrochloride compound preparations | Gastro-Intestinal System | 8,310 |
|
Mesalazine 500mg modified-release tablets
0105010B0AAAIAI
|
Mesalazine | Mesalazine (Systemic) | Gastro-Intestinal System | 8,174 |
|
Ursodeoxycholic acid 250mg tablets
0109010U0AABLBL
|
Ursodeoxycholic acid | Ursodeoxycholic acid | Gastro-Intestinal System | 7,772 |
|
Nexium 40mg gastro-resistant tablets (AstraZeneca)
0103050E0BBABAB
|
Nexium | Esomeprazole | Gastro-Intestinal System | 7,759 |
|
Nutrizym 22 gastro-resistant capsules
0109040N0BEACAZ
|
Nutrizym | Pancreatin | Gastro-Intestinal System | 7,665 |
|
Salofalk 1.5g gastro-resistant modified-release gran sachets
0105010B0BDAHAU
|
Salofalk | Mesalazine (Systemic) | Gastro-Intestinal System | 7,423 |
|
Mintec 0.2ml gastro-resistant capsules
0102000T0BCAAAA
|
Mintec | Peppermint oil | Gastro-Intestinal System | 7,416 |
|
Lactulose 10g/15ml oral solution 15ml sachets sugar free
0106040G0AAAGAG
|
Lactulose | Lactulose | Gastro-Intestinal System | 7,371 |
|
Omeprazole 10mg gastro-resistant tablets
0103050P0AABCBC
|
Omeprazole | Omeprazole | Gastro-Intestinal System | 7,269 |
|
Zoton FasTab 15mg
0103050L0BBADAG
|
Zoton | Lansoprazole | Gastro-Intestinal System | 7,188 |
|
Ispaghula husk 3.5g / Mebeverine 135mg efferv gran sach SF
0102000X0AAAAAA
|
Generic granules | Mebeverine hydrochloride compound preparations | Gastro-Intestinal System | 7,043 |
|
Losec MUPS 20mg gastro-resistant tablets
0103050P0BBAEAN
|
Losec | Omeprazole | Gastro-Intestinal System | 7,020 |
|
Ursodeoxycholic acid 300mg tablets
0109010U0AAAYAY
|
Ursodeoxycholic acid | Ursodeoxycholic acid | Gastro-Intestinal System | 6,821 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.